- Home
- CVAC vs NVAX Comparison
CVAC vs NVAX Comparison
Compare CVAC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- NVAX
- Stock Information
- Founded
- CVAC 2000
- NVAX 1987
- Country
- CVAC Germany
- NVAX United States
- Employees
- CVAC N/A
- NVAX N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVAC Health Care
- NVAX Health Care
- Exchange
- CVAC Nasdaq
- NVAX Nasdaq
- Market Cap
- CVAC 1.2B
- NVAX 1.3B
- IPO Year
- CVAC 2020
- NVAX 1995
- Fundamental
- Price
- CVAC $5.36
- NVAX $8.10
- Analyst Decision
- CVAC Hold
- NVAX Hold
- Analyst Count
- CVAC 3
- NVAX 5
- Target Price
- CVAC $6.83
- NVAX $9.80
- AVG Volume (30 Days)
- CVAC 411.0K
- NVAX 4.6M
- Earning Date
- CVAC 11-11-2025
- NVAX 11-11-2025
- Dividend Yield
- CVAC N/A
- NVAX N/A
- EPS Growth
- CVAC N/A
- NVAX N/A
- EPS
- CVAC 1.01
- NVAX 2.54
- Revenue
- CVAC $599,540,810.00
- NVAX $1,078,718,000.00
- Revenue This Year
- CVAC N/A
- NVAX $60.81
- Revenue Next Year
- CVAC $23.83
- NVAX N/A
- P/E Ratio
- CVAC $5.34
- NVAX $3.18
- Revenue Growth
- CVAC 675.15
- NVAX 9.22
- 52 Week Low
- CVAC $2.37
- NVAX $5.01
- 52 Week High
- CVAC $5.72
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- CVAC 45.73
- NVAX 42.78
- Support Level
- CVAC $5.34
- NVAX $8.24
- Resistance Level
- CVAC $5.41
- NVAX $9.34
- Average True Range (ATR)
- CVAC 0.04
- NVAX 0.52
- MACD
- CVAC -0.00
- NVAX -0.11
- Stochastic Oscillator
- CVAC 18.18
- NVAX 6.07
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.